CURRENT
ISSUE
1595
April 6, 2020

The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in treating it. Definitive answers are lacking, but some recommendations can be made. Updated information on COVID-19 is available from the CDC at www.cdc.gov/coronavirus/2019-ncov/hcp/index.html.

ACES AND ARBS — Patients with cardiovascular disease are at increased risk of...  Continue reading

More from Issue 1595
Previous Issue: 1594      March 23, 2020
Coming Soon
Trijardy XR - A Combination of 3 Old Drugs for Type 2 Diabetes
Topical Minocycline Foam (Amzeeq) for Acne
Drugs for Osteoarthritis
Intranasal Diazepam (Valtoco) and Midazolam (Nayzilam) for Seizure Clusters
Search
Donate
Subscribe
Conversation
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
FROM
ISSUE
1595

The FDA has approved two new drugs for sickle cell disease: crizanlizumab-tmca (Adakveo – Novartis), an IV P-selectin blocker, and voxelotor (Oxbryta – GBT), an oral hemoglobin S (HbS) polymerization inhibitor.

STANDARD TREATMENT — In sickle cell disease, elongated or sickle-shaped red blood cells obstruct small blood ... Continue reading

 Tweets